Bioheart Inc, a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announces an update on the phase I safety trial using adipose derived cells.
Approximately four years ago in April, 2010, Bioheart initiated a study using adipose derived stem cells (AdipoCell(TM)) in congestive heart failure patients. In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, five congestive heart failure patients were successfully treated in the initial pilot trial at Hospital Angeles Tijuana. Patients underwent a mini-lipoaspiration procedure where 60ccs of fat were removed.
This fat was processed to obtain the stromal vascular fraction (SVF) which
Medistem Inc. announced today positive safety data from the first 5 patients enrolled in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC) trial. The clinical trial uses the company’s “Universal Donor” Endometrial Regenerative Cells (ERC) to treat Congestive Heart Failure (CHF).
According to the study design, after 5 patients enter the trial, they must be observed for a two month time period before additional patients are allowed to enter the study. Patient data was analyzed by the study’s independent Data Safety Monitoring Board (DSMB), which concluded that based on lack of adverse effects,
Image via Wikipedia
Solving a longstanding mystery, scientists have found that the human heart continues to generate new cardiac cells throughout the life span, although the rate of new cell production slows with age.
The finding, published in the April 3 issue of Science, could open a new path for the treatment of heart diseases such as heart failure and heart attack, experts say.
“We find that the beating cells in the heart, cardiomyocytes, are renewed,” said lead researcher Dr. Jonas Frisen, a professor of stem cell research at the Karolinska Institute in Stockholm, Sweden. “It has previously not been known whether
James Eilert went on a 20-mile bike ride the other day! Why is that amazing?
Because18 months ago, the thought of getting on a bicycle was too much exertion for the Michigan native. In 2006, at the young age of 34, James suffered a major heart attack, which damaged his heart muscle.
The heart damage left James fatigued, exhausted and short of breath. It was increasingly difficult to meet the demands of his job as an automotive engineer. He was gasping for breath and sweating all the time. His ejection fraction (EF) had sunk to 20-25%. Feeling depressed,
Concha Herrera Arroyo, from El Pais
The Cardiology department and the Area of Cell Therapy of Cordoba hospital Reina Sofia are carrying out clinical tests with patients who have suffered from a severe heart attack. With the implantation of the patient’s stem cells, the heart regenerates thus improving its wall motion, that is, its cardiac performance.
Indeed for the last four years, the Area of Cell Therapy of Cordoba hospital, led by haematologist Dr. Concha Herrera, has been implementing a therapy program with adult stem cells in patients with heart-related problems. However, this therapy is not a service the hospital